GetLatka · Apr 2025
Estimates annual revenue around $900K, reports roughly 6 employees, and lists Adil Yusuf as CEO in its compiled company data.
AI-designed Protein Therapeutics
Company research
Public company, workplace, funding, and market signals
Overview
AI-native biotech designing custom affinity reagents and other protein tools for research teams and diagnostic developers, using AI/protein design plus wet-lab validation to deliver results in weeks rather than months.
Primary product
Custom affinity reagents
Founded
2021
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI protein design / affinity reagents
Offices
San Francisco, California, United States (HQ)
Boston, Massachusetts, United States
Business model
B2B custom reagent development
project-based collaborative R&D
consultative services for research and diagnostics
Funding
Stage
Seed / early-stage VC
Total raised
$125K
Latest round
Accelerator/Incubator · Sep 2021
Latest amount
$125K
People & investors
Work & culture
Small founder-led team with an interdisciplinary AI/protein-design focus, rapid project scoping, and an experimental-validation-oriented product process.
Product & market
Pricing
Custom, project-based engagement; consultation and project scoping are publicly offered as free, then work is scoped per target/application.
Differentiators
- —AI and protein design combined with experimental validation
- —Custom affinity reagents tailored to target and application
- —Delivery in weeks rather than months
- —Works across binding, detection, capture, and measurement use cases
Technology
Amazon S3
Amazon Web Services
Google Tag Manager
Amazon CloudFront
AWS Certificate Manager
Customers
Research teams
Diagnostic developers
Industry customers
Academia
Competitors
AI Proteins
Nabla Bio
Pando Bioscience
Seer
Biognosys
Scale & contact
Estimated revenue
under $1M
Latest news
Tracxn · Dec 2024
Profiles the company’s seed funding history and names Y Combinator as the lead investor in its latest visible round.
TechCrunch · Sep 2021
Early public coverage of Medium Biosciences as a YC Summer 2021 company; described the company as using machine learning to find new enzymes for biotech companies.
PitchBook
Shows multiple deal entries, including an accelerator/incubator round and later early-stage VC deal entries, and lists named investors including AIX Ventures, E14 Fund, Village Global, and SBXi.
Jobs and careers at Medium Biosciences
0 jobs at Medium Biosciences
No open positions
Check back later for new openings